Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Documenta Ophthalmologica
Published in: Documenta Ophthalmologica 3/2006

01-11-2006 | Original Paper

Retinal function and histopathology in rabbits treated with Topiramate

Authors: S. Kjellström, A. Bruun, B. Isaksson, T. Eriksson, S. Andréasson, V. Ponjavic

Published in: Documenta Ophthalmologica | Issue 3/2006

Login to get access

Abstract

Purpose

To evaluate retinal function and histopathology in rabbits treated orally with the anti-epileptic drug topiramate.

Methods

Six rabbits were treated with a daily oral dose of topiramate during a period of eight months. Six rabbits receiving water served as controls. Blood samples were analyzed for determination of topiramate serum levels in order to ensure successful drug exposition. Standardized full-field electroretinograms (ERGs) were performed before treatment and then at 2, 3 and 8 months during the treatment period. After terminating treatment the rabbits were sacrificed and the morphology of the sectioned retina was studied.

Results

After eight months of treatment the full-field ERG demonstrated normal rod function in treated and control rabbits, but the light adapted 30 Hz flicker b-wave amplitude was significantly reduced in the treated rabbits. This was the case for both the light adapted (Wilcoxon signed ranks test, P = 0.046) and the dark adapted (Wilcoxon signed ranks test, P = 0.028) 30 Hz flicker response from the treated rabbits. Retinal immunohistology revealed a severe accumulation of GABA in amacrine cells and in the inner plexiform layer in 4 of 6 treated rabbits compared to the controls.

Conclusions

Topiramate, orally administrated to rabbits, may cause a significant reduction of the retinal function demonstrated by the reduced b-wave amplitude in the full-field ERG, as well as changes in immunohistology characterized by a severe accumulation of GABA in the inner retina. The retinal dysfunction and the morphological changes indicate that topiramat may damage the retina, similarly to vigabatrin (another anti-epileptic drug).
Literature
1.
Roff Hilton EJ, Hosking SL, Betts T (2004) The effect of antiepileptic drugs on visual performance. Seizure 13:113–128CrossRef
2.
Czapinski P, Blaszczyk B, Czuczwar SJ (2005) Mechanism of action of antiepileptic drugs. Curr Top Med Chem 5:3–14PubMedCrossRef
3.
Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Brit Med J 314:180–181PubMed
4.
Harding GA (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Brit Med J 314:1694PubMed
5.
Wilson EA, Brodie MJ (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Brit Med J 314:1693PubMed
6.
Steinhoff J, Freudenthaler N, Paulus W (1997) The influence of established and new epileptic drugs on visual perception. Epilepsy Res 29:34–47
7.
Harding GF, Wild JM, Robertson KA et al (2000) Separating the retinal electrophysiological effects of vigabatrin: treatment versus field loss. Neurology 55:347–352PubMedCrossRef
8.
Coupland SG, Zackon DH, Leonard BC, Ross TM (2001) Vigabatrin effect on inner retinal function. Ophthalmology 109:1493–1498CrossRef
9.
Ponjavic V, Andréasson S (2001) Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102:63–72PubMedCrossRef
10.
11.
12.
Kaplan LM (2005) Pharmacological therapies for obesity. Gastroenterol Clin North Am 35:91–104CrossRef
13.
Li Z, Maglione M, Tu W et al (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532–546PubMed
14.
Halpern A, Mancini MC (2005) Diabesity: are weight loss medications effective? Treat Endocrinol 4:65–74PubMedCrossRef
15.
Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J (2005) Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev CD004096
16.
Pederson KJ, Roerig JL, Mitchell JE (2003) Towards the pharmacotherapy of eating disorders. Expert Opin Pharmacother 4:1659–1678PubMedCrossRef
17.
Hedges DW, Reimherr FW, Hoopes SP et al (2003) Treatment of bulimia nervosa with topiramate in a randomized double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychitry 64:1449–1454CrossRef
18.
Appolinarion JC, McElroy SL (2004) Pharmacological approaches in the treatment of binge eating disorder. Curr Drug Targets 5:301–307CrossRef
19.
De Bernardi C, Ferraris S, D´Inella P, Do F, Torre E (2005) Topiramate for binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 29:339–341PubMedCrossRef
20.
Winkelman JW (2003) Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Med 4:243–246PubMedCrossRef
21.
Pappagallo M (2003) Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 25:2506–2538PubMedCrossRef
22.
Lewis DW, Dimond S, Scott D, Jones V (2004) Prophylactic treatment of pediatric migraine. Headache 44:230–237PubMedCrossRef
23.
Diamond M, Dahlof C, Papadopoulos G, Neto W, Wu SC (2005) Topiramate improves health-related quality of life when used to prevent migraine. Headache 45:1023–1030PubMedCrossRef
24.
Blumenfeld A (2005) Clinical approaches to migraine prophylaxis. Am J Manag Care 11:S55–61PubMed
25.
Brown JS, Papadopoulos G, Neumnn PJ, Friedman M, Miller JD, Menzin J (2005) Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 45:1012–1022PubMedCrossRef
26.
Bussone G, Diener HC, Pfeil J, Schwlen S (2005) Topiramate 100md/day in migraine prevention: pooled analysis of double-blind randomized controlled trials. Int J Clin Pract 59:961–968PubMedCrossRef
27.
D´Amico D, Grzzi L, Usai S, Moschiano F, Bussone G (2005) Topiramate in migraine prophylaxis. Neurol Sci 26:130–133CrossRef
28.
29.
Brandes JL (2005) Practical use of topiramate for migraine prevention. Headache 45:66–73CrossRef
30.
White HS (2005) Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 45:S48–56PubMedCrossRef
31.
Campistol J, Campos J, Casa C, Herranz JL (2005) Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 20:251–253PubMed
32.
Wang PW, Ketter TA, Becker OV, Nowakowska C (2003) New anticonvulsant medication uses in bipolar disorder. CNS Spectr 8:941–947
33.
Dunner DL (2005) Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 7:307–325PubMedCrossRef
34.
Gajwani P, Fortshoff A, Muzina D et al (2005) Antiepileptic drugs in mood-disordered patients. Epilepsia 46:38–44PubMedCrossRef
35.
36.
Janowsky DS, Kraus JE, Barnhill J, Elmir B, Davis JM (2003) Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled, an open-label retrospective study. J Clin Psychopharmacol 23:500–504PubMedCrossRef
37.
Gatto EM, Roca MC, Raina G, Micheli F (2003) Low doses of topiramate are effective in essential tremor: a report of three cases. Clin Neuropharmacol 26:294–296PubMedCrossRef
38.
Fhager B, Meiri IM, Sjogren M, Edman A (2003) Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study. Int Psychogeriatr 15:307–309PubMedCrossRef
39.
Asnis GM, Kohn SR, Henderson M, Brown NL (2004) SSRIs versus non SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs 64:383–404PubMedCrossRef
40.
Nickel MK, Nickel C, Kpln P et al (2005) Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 57:495–499PubMedCrossRef
41.
Tiihonen J, Hlonen P, Wahlbeck K et al (2005) Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 66:1012–1015PubMedCrossRef
42.
Arnone D (2005) Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 16:5CrossRef
43.
Anderson N, Oliver MN (2003) Oral topiramate effective for alcoholism. J Fam Pract 52:682–683, 687
44.
Raguraman J, Priyadharshini RK, Chandrasekarn (2005) Effects of topiramate in alcohol dependence. Aust N Z J Psychiatry 39:736–737
45.
Johnson BA, Ait-Daoud N, Akhtar FZ, Jvors MA (2005) Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 165:1600–1605PubMedCrossRef
46.
Book SW, Myrick H (2005) Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs 14:371–376PubMedCrossRef
47.
Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F (2005) Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 37:37–40
48.
Sofouglu M, Kosten TR (2005) Novel approaches to the treatment of cocaine addiction. CNS Drugs 19:13–25CrossRef
49.
Artemowitz B, Sobaniec W (2005) Neuroprotection possibilities in epileptic children. Rocz Akad Med Bialymst 50:91–95
50.
Al Ajlouni S, Shorman A, Daoud AS. The efficacy of topiramate on refractory epilepsy in infants and young children: a multi-center clinical trial. Seizure 2005: [Epub ahead of print]
51.
Hershey AD, Winner PK (2005) Pediatric migraine: recognition and treatment. J Am Osteopath Assoc 105:2S–8SPubMed
52.
Gjörloff K, Andréasson S, Ehinger B (2004) Standardized full-field electroretinography in rabbits. Doc Ophthalmol 109:163–168PubMedCrossRef
53.
Ponjavic V, Gränse L, Kjellström S, Andréasson S, Bruun A (2004) Alterations in electroretinograms and retinal morphology in rabbits treated with Vigabatrin. Doc Ophthalmol 00:1–9
54.
Marmor MF, Holder GE, Seelinger MW, Yamamoto S (2004) International Society for Clinical Electrophysiology of Vision. Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107–114PubMedCrossRef
55.
Hauser W (1997) Incidence and prevalence. In: Engel J, Pedley T (eds) Epilepsy: a comprehensive textbook. Lippincott-Raven Publishers, Philadelphia, pp. 47–57
56.
Fraunfelder FW, Fraunfelder F (2004) Adverse ocular drug reactions recently identified by the national registry of drug-induced ocular side effects. Ophthalmology 111:1275–1279PubMedCrossRef
57.
Foroozan R, Buono LM (2003) Clinical challenges: foggy visual field defect. Surv Ophthalmol 48:447–451PubMedCrossRef
58.
Vaphiades MS, Mason J (2003) Letter to the editor: foggy visual field defect. Surv Ophthalmol 49:266–267CrossRef
Metadata
Title
Retinal function and histopathology in rabbits treated with Topiramate
Authors
S. Kjellström
A. Bruun
B. Isaksson
T. Eriksson
S. Andréasson
V. Ponjavic
Publication date
01-11-2006
Publisher
Springer-Verlag
Published in
Documenta Ophthalmologica / Issue 3/2006
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-006-9027-8

Other articles of this Issue 3/2006

Documenta Ophthalmologica 3/2006 Go to the issue

Original Paper

ISCEV Standard for Clinical Electro-oculography (EOG) 2006

CLINICAL CASE REPORTS

The value of VEP in the diagnosis and post-operative monitoring of meningioma

CLINICAL CASE REPORTS

A teenager with nightblindness and cystic maculopathy: enhanced S cone syndrome (Goldmann-Favre syndrome)

Original Paper

Phototoxic effects of commercial photographic flash lamp on rat eyes

Original paper

The influence of luminance on the multifocal ERG

Clinical Case Reports

Negative scotopic ERG and photopic ERG ON response impairment in a patient with normal dark adaptation